Skip to main content
Erschienen in: Supportive Care in Cancer 8/2016

30.03.2016 | Original Article

Feasibility of an interactive electronic self-report tool for oral cancer therapy in an outpatient setting

verfasst von: Marika Rasschaert, Silke Helsen, Christian Rolfo, Ilse Van Brussel, Jo Ravelingien, Marc Peeters

Erschienen in: Supportive Care in Cancer | Ausgabe 8/2016

Einloggen, um Zugang zu erhalten

Abstract

Background

The introduction of oral anti-cancer agents provides a convenient administration route for chronic cancer treatment to outpatients. Health information technology through web-based applications or other electronic tools can offer a platform to improve treatment compliance, symptom management, and patient-provider communication.

Purpose

The purposes of this study were to test the feasibility and clinical utility of an electronic self-report device (RemeCoach) for patients or their caregivers and to register and prospectively evaluate the quality of data generated.

Patients and methods

Patients using Teysuno® (S-1) for advanced gastrointestinal carcinoma used a pre-programmed device in order to register compliance to treatment and six clinical parameters. Real-time data were collected onto a central platform, which processed the data by an algorithm. This algorithm stratified the data into different grades based on the Common Terminology Criteria for Adverse Events (CTCAE v4.0).

Results

From December 2013 to March 2014, 11 patients (5 men, 6 women) were enrolled. Compliance to the device was high, six patients (55 %) registered timely intake of medication (demonstrating >95 % treatment compliance). Agreement between patients’ and clinicians’ reported toxicity was substantial for nausea, but discrepant for fatigue, hand-foot syndrome, and mucositis.

Conclusion

The use of an interactive self-report tool is feasible, reliable, and acceptable to outpatients. The RemeCoach and the algorithm devised will be further developed as an interactive patient-reported outcome (PRO) system, to improve early detection of side effects in an outpatient setting. Further studies are needed to confirm these data and to explore the relationship between optimal patient support and efficacy of treatment.
Literatur
1.
Zurück zum Zitat Basch E, Jia X, Heller G, et al. (2009) Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes. J Natl Cancer Inst 101:1624–1632CrossRefPubMedPubMedCentral Basch E, Jia X, Heller G, et al. (2009) Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes. J Natl Cancer Inst 101:1624–1632CrossRefPubMedPubMedCentral
2.
Zurück zum Zitat Bodenheimer T, Wagner E, Grumbach K (2002) Improving primary care for patients with chronic illness. Jama 288:1775–1779CrossRefPubMed Bodenheimer T, Wagner E, Grumbach K (2002) Improving primary care for patients with chronic illness. Jama 288:1775–1779CrossRefPubMed
3.
Zurück zum Zitat Bodenheimer T, Wagner E, Grumbach K (2002) Improving primary care for patients with chronic illness. the chronic care model, part 2. Jama 288:1909–1914CrossRefPubMed Bodenheimer T, Wagner E, Grumbach K (2002) Improving primary care for patients with chronic illness. the chronic care model, part 2. Jama 288:1909–1914CrossRefPubMed
4.
Zurück zum Zitat Lipscomb J, Reeve BB, Clauser SB, et al. (2007) Patient-reported outcomes assessment in cancer trials: taking stock, moving forward. J Clin Oncol 25:5133–5140CrossRefPubMed Lipscomb J, Reeve BB, Clauser SB, et al. (2007) Patient-reported outcomes assessment in cancer trials: taking stock, moving forward. J Clin Oncol 25:5133–5140CrossRefPubMed
5.
Zurück zum Zitat Di Maio M, Gallo C, Leighl N, et al. (2015) Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials. J Clin Oncol 33:910–915CrossRefPubMed Di Maio M, Gallo C, Leighl N, et al. (2015) Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials. J Clin Oncol 33:910–915CrossRefPubMed
6.
Zurück zum Zitat Christie A, Dagfinrud H, Dale O, et al. (2014) Collection of patient-reported outcomes; text messages on mobile phones provide valid scores and high response rates. BMC Med Res Methodol 14:52–57CrossRefPubMedPubMedCentral Christie A, Dagfinrud H, Dale O, et al. (2014) Collection of patient-reported outcomes; text messages on mobile phones provide valid scores and high response rates. BMC Med Res Methodol 14:52–57CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Basch E, Abernathy AP, Mullins CD, et al. (2012) Recommendations for incorporating patient-reported outcomes into clinical comparative-effectiveness research in adult oncology. J Clin Oncol 30:4249–4255CrossRefPubMed Basch E, Abernathy AP, Mullins CD, et al. (2012) Recommendations for incorporating patient-reported outcomes into clinical comparative-effectiveness research in adult oncology. J Clin Oncol 30:4249–4255CrossRefPubMed
8.
Zurück zum Zitat Ajani JA, Rodriguez W, Bodoky G, et al. (2010) Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. J Clin Oncol 28:1547–1553CrossRefPubMed Ajani JA, Rodriguez W, Bodoky G, et al. (2010) Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. J Clin Oncol 28:1547–1553CrossRefPubMed
9.
Zurück zum Zitat Shirasaka T, Shimamato Y, Ohshimo H, et al. (1996) Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anti-Cancer Drugs 7(5):548–557CrossRefPubMed Shirasaka T, Shimamato Y, Ohshimo H, et al. (1996) Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anti-Cancer Drugs 7(5):548–557CrossRefPubMed
10.
Zurück zum Zitat Basch E, Artz D, Dulko D, et al. (2005) Patient online self-reporting of toxicity symptoms during chemotherapy. J Clin Oncol 23:3552–3561CrossRefPubMed Basch E, Artz D, Dulko D, et al. (2005) Patient online self-reporting of toxicity symptoms during chemotherapy. J Clin Oncol 23:3552–3561CrossRefPubMed
11.
12.
Zurück zum Zitat Schoffski P (2004) The modulated oral fluoropyrimidine prodrug S-1, and its use in gastrointestinal cancer and other solid tumors. Anti-Cancer Drugs 15(2):85–106CrossRefPubMed Schoffski P (2004) The modulated oral fluoropyrimidine prodrug S-1, and its use in gastrointestinal cancer and other solid tumors. Anti-Cancer Drugs 15(2):85–106CrossRefPubMed
13.
Zurück zum Zitat Basch E, Iasonos A, Barz A, et al. (2007) Long-term toxicity monitoring via electronic patient-reported outcomes in patients receiving chemotherapy. J Clin Oncol 25:5374–5380CrossRefPubMed Basch E, Iasonos A, Barz A, et al. (2007) Long-term toxicity monitoring via electronic patient-reported outcomes in patients receiving chemotherapy. J Clin Oncol 25:5374–5380CrossRefPubMed
14.
Zurück zum Zitat Judson T, Bennett A, Rogak L, et al. (2013) Feasibility of long-term patient self-reporting of toxicities from home via the internet during routine chemotherapy. J Clin Oncol 31:2580–2585CrossRefPubMedPubMedCentral Judson T, Bennett A, Rogak L, et al. (2013) Feasibility of long-term patient self-reporting of toxicities from home via the internet during routine chemotherapy. J Clin Oncol 31:2580–2585CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Snyder CF, Aaronson NKm Choucair AK, et al. (2012) Implementing patient reported outcomes assessment in clinical practice: a review of the options and considerations. Qual Life Res 21:1305–1314CrossRefPubMed Snyder CF, Aaronson NKm Choucair AK, et al. (2012) Implementing patient reported outcomes assessment in clinical practice: a review of the options and considerations. Qual Life Res 21:1305–1314CrossRefPubMed
16.
Zurück zum Zitat Howell D, Molloy S, Wilkinson K, et al. (2015) Patient-reported outcomes in routine cancer clinical practice: a scoping review of use, impact on health outcomes, and implementation factors. Ann Oncol 26(9):1846–1858CrossRefPubMed Howell D, Molloy S, Wilkinson K, et al. (2015) Patient-reported outcomes in routine cancer clinical practice: a scoping review of use, impact on health outcomes, and implementation factors. Ann Oncol 26(9):1846–1858CrossRefPubMed
17.
Zurück zum Zitat Reeve B, Mitchell S, Dueck A, et al. (2014) Recommended patient-reported core set of symptoms to measure in adult cancer treatment trials. JNCI 106(7):dju 129. doi:10.1093/jnci/dju129 CrossRef Reeve B, Mitchell S, Dueck A, et al. (2014) Recommended patient-reported core set of symptoms to measure in adult cancer treatment trials. JNCI 106(7):dju 129. doi:10.​1093/​jnci/​dju129 CrossRef
Metadaten
Titel
Feasibility of an interactive electronic self-report tool for oral cancer therapy in an outpatient setting
verfasst von
Marika Rasschaert
Silke Helsen
Christian Rolfo
Ilse Van Brussel
Jo Ravelingien
Marc Peeters
Publikationsdatum
30.03.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
Supportive Care in Cancer / Ausgabe 8/2016
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-016-3186-2

Weitere Artikel der Ausgabe 8/2016

Supportive Care in Cancer 8/2016 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.